

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/14, 9/51		A1	(11) International Publication Number: WO 96/24335
			(43) International Publication Date: 15 August 1996 (15.08.96)
(21) International Application Number: PCT/US96/01439		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 6 February 1996 (06.02.96)			
(30) Priority Data: 08/386,026 9 February 1995 (09.02.95) US 08/444,796 19 May 1995 (19.05.95) US			
(71) Applicant: NANOSYSTEMS L.L.C. [US/US]; Building 1, 1250 South Collegeville Road, Collegeville, PA 19426 (US).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventor: WONG, Sui-Ming; 159 Derr Drive, Collegeville, PA 19426 (US).			
(74) Agents: WEST, Paul, B.; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US) et al.			
(54) Title: SUGAR BASE SURFACTANT FOR NANOCRYSTALS			
(57) Abstract			
<p>Dispersible particles consisting essentially of a crystalline drug substance having a surface modifier having formula (I), wherein R is phenyl-(CH₂)₁₀CO or C₁₂H₂₅NHCO adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm, methods for the preparation of such particles and dispersions containing the particles. Pharmaceutical compositions containing the particles exhibit unexpected bioavailability and are useful in methods of treating mammals.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

WO 96/24335

PCT/US96/01439

SUGAR BASE SURFACTANT FOR NANOCRYSTALS
FIELD OF THE INVENTION

This invention relates to drug particles, methods for the preparation thereof and
5 dispersions containing the particles. This invention further relates to the use of such particles in pharmaceutical compositions and methods of treating mammals.

BACKGROUND OF THE INVENTION

10 Bioavailability is the degree to which a drug becomes available to the target tissue after administration. Many factors can affect bioavailability including the dosage form and various properties, e.g., dissolution rate of the
15 drug. Poor bioavailability is a significant problem encountered in the development of pharmaceutical compositions, particularly those containing an active ingredient that is poorly soluble in water. Poorly water soluble drugs,
20 i.e., those having a solubility less than about 10 mg/ml, tend to be eliminated from the gastrointestinal tract before being absorbed into the circulation. Moreover, poorly water soluble drugs tend to be unsafe for intravenous
25 administration techniques, which are used primarily in conjunction with fully soluble drug substances.

It is known that the rate of dissolution of a particulate drug can
30 increase with increasing surface area, i.e., decreasing particle size. Consequently, methods of making finely divided drugs have been

WO 96/24335

PCT/US96/01439

-2-

studied and efforts have been made to control the size and size range of drug particles in pharmaceutical compositions. For example, dry milling techniques have been used to reduce particle size and hence influence drug absorption. However, in conventional dry milling, as discussed by Lachman, et al., The Theory and Practice of Industrial Pharmacy, Chapter 2, "Milling", p. 45, (1986), the limit of fineness is reached in the region of 100 microns (100,000 nm) when material cakes on the milling chamber. Lachman, et al. note that wet grinding is beneficial in further reducing particle size, but that flocculation restricts the lower particle size limit to approximately 10 microns (10,000 nm). However, there tends to be a bias in the pharmaceutical art against wet milling due to concerns associated with contamination. Commercial airjet milling techniques have provided particles ranging in average particle size from as low as about 1 to 50 μm (1,000 - 50,000 nm).

Other techniques for preparing pharmaceutical compositions include loading drugs into liposomes or polymers, e.g., during emulsion polymerization. However, such techniques have problems and limitations. For example, a lipid soluble drug is often required in preparing suitable liposomes. Further, unacceptably large amounts of the liposome or polymer are often required to prepare unit drug doses. Further still, techniques for preparing such pharmaceutical compositions tend to be complex. A principal technical difficulty encountered with emulsion polymerization is the removal of contaminants, such as unreacted monomer or initiator, which can be toxic, at the end of the manufacturing process.

U. S. Patent 4,540,602 (Motoyama et al.) discloses a solid drug pulverized in an aqueous solution of a water-soluble high molecular substance using a wet

WO 96/24335

PCT/US96/01439

-3-

grinding machine. However, Motoyama et al. teach that as a result of such wet grinding, the drug is formed into finely divided particles ranging from 0.5 μm (500 nm) or less to 5 μm (5,000 nm) in diameter.

5 EPO 275,796 describes the production of colloiddally dispersible systems comprising a substance in the form of spherical particles smaller than 500 nm. However, the method involves a precipitation effected by mixing a solution of the substance and a miscible
10 non-solvent for the substance and results in the formation of non-crystalline nonoparticles. Furthermore, precipitation techniques for preparing particles tend to provide particles contaminated with solvents. Such solvents are often toxic and can be
15 very difficult, if not impossible, to adequately remove to pharmaceutically acceptable levels to be practical.

U. S. Patent 4,107,288 describes particles in the size range from 10 to 1,000 nm containing a biologically or pharmacodynamically active material.
20 However, the particles comprise a crosslinked matrix of macromolecules having the active material supported on or incorporated into the matrix.

U.S. Patent 5,145,684 describes unique nanoparticles comprising a crystal- drug substance
25 having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm, methods for the preparation of such particles and dispersions containing the particles. Pharmaceutical
30 compositions containing the particles exhibit unexpected bioavailability and are useful in methods of treating mammals.

It would be desirable to provide even more stable dispersible drug particles in the submicron size range
35 which can be readily prepared and which do not appreciably flocculate or agglomerate due to

WO 96/24335

PCT/US96/01439

-4-

interparticle attractive forces and do not require the presence of a crosslinked matrix. Moreover, it would be highly desirable to provide pharmaceutical compositions having enhanced bioavailability over those described in U.S. Patent 5,145,684.

SUMMARY OF THE INVENTION

We have discovered stable, dispersible drug nanoparticles and a method for preparing such particles by wet milling in the presence of grinding media in conjunction with a specific surface modifier. The particles can be formulated into pharmaceutical compositions exhibiting remarkably high bioavailability.

More specifically, in accordance with this invention, there are provided particles consisting essentially of a crystalline drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm.

This invention also provides a stable dispersion consisting essentially of a liquid dispersion medium and the above-described particles dispersed therein.

In another embodiment of the invention, there is provided a method of preparing the above-described particles comprising the steps of dispersing a drug substance in a liquid dispersion medium and applying mechanical means in the presence of grinding media to reduce the particle size of the drug substance to an effective average particle size of less than about 400 nm. The particles can be reduced in size in the presence of a surface modifier. Alternatively, the particles can be contacted with the surface modifier after attrition.

In a particularly valuable and important embodiment of the invention, there is provided a

WO 96/24335

PCT/US96/01439

-5-

pharmaceutical composition comprising the above-described particles and a pharmaceutically acceptable carrier therefor. Such pharmaceutical composition is useful in a method of treating mammals.

5 It is an advantageous feature that a wide variety of surface modified drug nanoparticles free of unacceptable contamination can be prepared in accordance with this invention.

10 It is another advantageous feature of this invention that there is provided a simple and convenient method for preparing drug nanoparticles by wet milling in conjunction with the surface modifier.

Another particularly advantageous feature of this invention is that pharmaceutical compositions are
15 provided exhibiting unexpectedly high bioavailability.

Still another advantageous feature of this invention is that pharmaceutical compositions containing poorly water soluble drug substances are provided which are suitable for intravenous
20 administration techniques.

Other advantageous features will become readily apparent upon reference to the following Description of Preferred Embodiments.

25 DESCRIPTION OF PREFERRED EMBODIMENTS

This invention is based on the discovery that drug particles having an extremely small effective average particle size can be prepared by wet milling in the presence of grinding media in conjunction with a
30 specific surface modifier, and that such particles are stable and do not appreciably flocculate or agglomerate due to interparticle attractive forces and can be formulated into pharmaceutical compositions exhibiting unexpectedly high bioavailability. While the invention
35 is described herein primarily in connection with its preferred utility, i.e., with respect to

WO 96/24335

PCT/US96/01439

-6-

nanoparticulate drug substances for use in pharmaceutical compositions, it is also believed to be useful in other applications such as the formulation of particulate cosmetic compositions and the preparation
5 of particulate dispersions for use in image and magnetic recording elements.

The particles of this invention comprise a drug substance. The drug substance exists as a discrete, crystalline phase. The crystalline phase differs from
10 a non-crystalline or amorphous phase which results from precipitation techniques, such as described in EPO 275,796 cited above.

The invention can be practiced with a wide variety of drug substances. The drug substance preferably is
15 present in an essentially pure form. The drug substance must be poorly soluble and dispersible in at least one liquid medium. By "poorly soluble" it is meant that the drug substance has a solubility in the liquid dispersion medium of less than about 10 mg/ml,
20 and preferably of less than about 1 mg/ml. A preferred liquid dispersion medium is water. However, the invention can be practiced with other liquid media in which a drug substance is poorly soluble and dispersible including, for example, aqueous salt
25 solutions, safflower oil and solvents such as ethanol, t-butanol, hexane and glycol. The pH of the aqueous dispersion media can be adjusted by techniques known in the art.

Suitable drug substances can be selected from a
30 variety of known classes of drugs including, for example, analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics,
35 antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic

WO 96/24335

PCT/US96/01439

-7-

agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac
5 inotropic agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immuriological agents, lipid regulating
10 agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents,
15 vasodilators and xanthines. Preferred drug substances include those intended for oral administration and intravenous administration. A description of these classes of drugs and a listing of species within each class can be found in Martindale, *The Extra*
20 *Pharmacopoeia*, Twenty-ninth Edition, The Pharmaceutical Press, London, 1989, the disclosure of which is hereby incorporated by reference in its entirety. The drug substances are commercially available and/or can be prepared by techniques known in the art.

25 Representative illustrative species of drug substances useful in the practice of this invention include:


17-pregno-2,4-dien-20-yno-[2,3-d]-isoxazol-
17-ol
30 (Danazol);
5,17,-1'-(methylsulfonyl)-1'H-pregn-20-yno
[3,2-c]-pyrazol-17-ol (Steroid A);
piposulfam;
piposulfan;
35 camptothecin; and
ethyl-3,5-diacetoamido-2,4,6-triiodobenzoate

WO 96/24335

PCT/US96/01439

-8-

In particularly preferred embodiments of the invention, the drug substance is a diagnostic agent surface modifier having the structure:



5

wherein R is $\text{Ph}(\text{CH}_2)_{10}\text{CO}$ wherein Ph is phenyl or $\text{C}_{12}\text{H}_{25}\text{NHCO}$ adsorbed on the surface thereof.

The particular surface modifier provides the nanodispersible particles with unexpectedly reduced mean particle size and limiting the particle size growth during terminal sterilization of the nanocrystal formulations.

The surface modifier of this invention is the discovery of Ian Newington and Katie Adams.

The surface modifier is adsorbed on the surface of the drug substance in an amount sufficient to maintain an effective average particle size of less than about 400 nm. The surface modifier does not chemically react with the drug substance or itself. Furthermore, the individually adsorbed molecules of the surface modifier are essentially free of intermolecular crosslinkages.

As used herein, particle size refers to a number average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, or disk centrifugation. By "an effective average particle size of less than about 400 nm" it is meant that at least 90% of the particles have a weight average particle

WO 96/24335

PCT/US96/01439

-9-

size of less than about 400 nm when measured by the above-noted techniques. In preferred embodiments of the invention, the effective average particle size is less than about 250 nm. In some embodiments of the invention, an effective average particle size of less than about 100 nm has been achieved. With reference to the effective average particle size, it is preferred that at least 95% and, more preferably, at least 99% of the particles have a particle size less than the effective average, e.g., 400 nm. In particularly preferred embodiments, essentially all of the particles have a size less than 400 nm. In some embodiments, essentially all of the particles have a size less than 250 nm.

The particles of this invention can be prepared in a method comprising the steps of dispersing a drug substance in a liquid dispersion medium and applying mechanical means in the presence of grinding media to reduce the particle size of the drug substance to an effective average particle size of less than about 400 nm. The particles can be reduced in size in the presence of a surface modifier. Alternatively, the particles can be contacted with a surface modifier after attrition.

A general procedure for preparing the particles of this invention is set forth below. The drug substance selected is obtained commercially and/or prepared by techniques known in the art in a conventional coarse form. It is preferred, but not essential, that the particle size of the coarse drug substance selected be less than about 100 μm as determined by sieve analysis. If the coarse particle size of the drug substance is greater than about 100 μm , then it is preferred that the particles of the drug substance be reduced in size to less than 100 μm using a conventional milling method such as airjet or fragmentation milling.

WO 96/24335

PCT/US96/01439

-10-

The coarse drug substance selected can then be added to a liquid medium in which it is essentially insoluble to form a premix. The concentration of the drug substance in the liquid medium can vary from about 5 0.1 - 60%, and preferably is from 5 - 30% (w/w). It is preferred, but not essential, that the surface modifier be present in the premix. The concentration of the surface modifier can vary from about 0.1 to about 90%, and preferably is 1 - 75%, more preferably 20-60%, by 10 weight based on the total combined weight of the drug substance and surface modifier. The apparent viscosity of the premix suspension is preferably less than about 1000 centipoise

The premix can be used directly by subjecting it 15 to mechanical means to reduce the average particle size in the dispersion to less than 400 nm. It is preferred that the premix be used directly when a ball mill is used for attrition. Alternatively, the drug substance and, optionally, the surface modifier, can be dispersed 20 in the liquid medium using suitable agitation, e.g., a roller mill or a Cowles type mixer, until a homogeneous dispersion is observed in which there are no large agglomerates visible to the naked eye. It is preferred that the premix be subjected to such a premilling 25 dispersion step when a recirculating media mill is used for attrition.

The mechanical means applied to reduce the particle size of the drug substance conveniently can take the form of a dispersion mill. Suitable 30 dispersion mills include a ball mill, an attritor mill, a vibratory mill, and media mills such as a sand mill and a bead mill. A media mill is preferred due to the relatively shorter milling time required to provide the intended result, i.e., the desired reduction in 35 particle size. For media milling, the apparent viscosity of the premix preferably is from about 100 to

WO 96/24335

PCT/US96/01439

-11-

about 1000 centipoise. For ball milling, the apparent viscosity of the premix preferably is from about 1 up to about 100 centipoise. Such ranges tend to afford an optimal balance between efficient particle

5 fragmentation and media erosion.

The grinding media for the particle size reduction step can be selected from rigid media preferably spherical or particulate in form having an average size less than about 3 mm and, more preferably, less than
10 about 1 mm. Such media desirably can provide the particles of the invention with shorter processing times and impart less wear to the milling equipment. The selection of material for the grinding media is not believed to be critical. We have found that zirconium
15 oxide, such as 95% ZrO stabilized with magnesia, zirconium silicate, and glass grinding media provide particles having levels of contamination which are believed to be acceptable for the preparation of pharmaceutical compositions. However, other media,
20 such as stainless steel, titania, alumina, and 95% ZrO stabilized with yttrium, are expected to be useful. Preferred media have a density greater than about 3 g/cm³.

The attrition time can vary widely and depends
25 primarily upon the particular mechanical means and processing conditions selected. For ball mills, processing times of up to five days or longer may be required. On the other hand, processing times of less than 1 day (residence times of one minute up to several
30 hours) have provided the desired results using a high shear media mill.

The particles must be reduced in size at a temperature which does not significantly degrade the drug substance. Processing temperatures of less than
35 about 30 - 40°C are ordinarily preferred. If desired, the processing equipment can be cooled with

WO 96/24335

PCT/US96/01439

-12-

conventional cooling equipment. The method is conveniently carried out under conditions of ambient temperature and at processing pressures which are safe and effective for the milling process. For example, 5 ambient processing pressures are typical of ball mills, attritor mills and vibratory mills. Processing pressures up to about 20 psi (1.4 kg/cm²) are typical of media milling.

The surface modifier, if it was not present in the 10 premix, must be added to the dispersion after attrition in an amount as described for the premix above. Thereafter, the dispersion can be mixed, e.g., by shaking vigorously. Optionally, the dispersion can be subjected to a sonication step, e.g., using an 15 ultrasonic power supply. For example, the dispersion can be subjected to ultrasonic energy having a frequency of 20 - 80 kHz for a time of about 1 to 120 seconds.

The relative amount of drug substance and surface 20 modifier can vary widely and the optimal amount of the surface modifier can depend, for example, upon the particular drug substance and surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, etc. The 25 surface modifier preferably is present in an amount of about 0.1-10 mg per square meter surface area of the drug substance. The surface modifier can be present in an amount of 0.1-90%, preferably 20-60% by weight based on the total weight of the dry particle.

30 The resulting dispersion of this invention is stable and consists of the liquid dispersion medium and the above-described particles. The dispersion of surface modified drug nanoparticles can be spray coated onto sugar spheres or onto a pharmaceutical excipient 35 in a fluid-bed spray coater by techniques well known in the art.

WO 96/24335

PCT/US96/01439

-13-

Pharmaceutical compositions according to this invention include the particles described above and a pharmaceutically acceptable carrier therefor. Suitable pharmaceutically acceptable carriers are well known to those skilled in the art. These include non-toxic physiologically acceptable carriers, adjuvants or vehicles for parenteral injection, for oral administration in solid or liquid form, for rectal administration, and the like. A method of treating a mammal in accordance with this invention comprises the step of administering to the mammal in need of treatment an effective amount of the above-described pharmaceutical composition. The selected dosage level of the drug substance for treatment is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore, depends upon the particular drug substance, the desired therapeutic effect, on the route of administration, on the desired duration of treatment and other factors. As noted, it is a particularly advantageous feature that the pharmaceutical compositions of this invention exhibit unexpectedly high bioavailability as illustrated in the examples which follow. Furthermore, it is contemplated that the drug particles of this invention provide more rapid onset of drug action and decreased gastrointestinal irritancy.

It is contemplated that the pharmaceutical compositions of this invention will be particularly useful in oral and parenteral, including intravenous, administration applications. It is expected that poorly water soluble drug substances, which prior to this invention, could not have been administered intravenously, may be administered safely in accordance with this invention. Additionally, drug substances which could not have been administered orally due to

WO 96/24335

PCT/US96/01439


-14-

poor bioavailability may be effectively administered in accordance with this invention.

The following Examples further illustrate the invention.

5

Example 1: Preparation of SA90HEA



To a solution of lactobionic acid (17.92g, 50mmol, 2 equivs. Aldrich 97%) in DMF (Dimethylformamide, 100ml, dried over 4A° molecular sieves). The reaction mixture was stirred at 70°C under argon for 18 hours. The solution was cooled to 50°C. The resulting product was N, N10-triethylenetetramine-bislactobionamide. N4,N7-diphenylundecanoyl-N1,N10-triethylenetetramine-bislactobionamide-SA90HEA as prepared by dissolving phenylundecanoic acid (13.12g, 50mmol, 2 equivs. Eastman Chemicals 99%) in diethyl ether (40ml) and cooling in an ice-bath. Triethylamine (5.06g, 50mmol, 2 equivs, Prolabo) was added followed by ethyl chloroformate (5.53g, 51mmol, 2.04 equivs. Lancaster), the mixture was stirred well. After 30 mins. filtered into a solution of N1, N10-triethylenetetraminebislactobionamide (20.67g, 25mmol, 1 equiv) in DMF (100ml, dried over 4A° molecular sieves) and washed well with diethyl ether. The mixture was stirred at 50°C for 6 hours. After cooling to room temperature, the solvent was evaporated under reduced pressure to leave an orange crystalline material, which was washed with diethyl ether,

WO 96/24335


PCT/US96/01439

-15-

collected by Buchner filtration and briefly dried under high vacuum to leave an orange powder (30.72g, 93% yield). A portion of this material (13g) was then dissolved in distilled water (40ml) and stirred with
 5 Amberlite IRA-420(OH) resin (BDH) at pH=10 for 40 mins. The resin was removed by buchner filtration and the product was obtained after freeze drying overnight which removed the water. SA90HEA was obtained as a fine pale yellow powder (7.47g, 57% yield).

10

Example 2: Preparation of SA90HEG



N4,N7-didodecylisocyanato-N1,N10-triethylenetetramine-bislactobionamide - SA90HEG was prepared by adding Dodecyl isocyanate (10.57g, 50mmol, 2 equivs. Eastman Chemicals 95%) to a solution of N1, N10-triethylenetetraminebislactobionamide (20.67g, 25mmol, 1 equiv) in DMF (100ml, dried over 4A°
 15 molecular sieves). The reaction mixture was heated at 50°C under argon for 7 hours. After cooling to room temperature, the solvent was evaporated under reduced pressure to leave a yellow crystalline material, which was washed with diethyl ether, collected by Buchner filtration and briefly dried under high vacuum to leave
 20 a yellow powder (29.15g, 93% yield). A portion of this material (16g) was then dissolved in distilled water (50ml) and stirred with Amberlite IRA-420(OH) resin (BDH) at pH=10 for 40 mins. The resin was removed by Buchner filtration and the product was obtained after

WO 96/24335

PCT/US96/01439

-16-

freeze drying overnight which removed the water.
SA90HEG was obtained as a fine cream powder (11.19g,
70% yield).

5 Examples 3-6

The following formulations were prepared at 15%
diagnostic agent and 4% surfactant (w/v). A 6% stock
solution was prepared by dissolving 600 mg of SA90HEA
and SA90HEG in 10 ml deionized water. To each 15 ml
10 amber colored bottle, 7.5 ml of 6% stock surfactant
solution and 0.994 ml deionized water were added. The
sample bottle was sealed and placed on a roller mill
running at 160 rpm for 7 days. At day 7, aliquot f
samples were diluted 100 fold with deionized water for
15 particle size measurement by Photon Correlation
Spectroscopy (Microtrac).


For terminal sterilization, 1 ml of nanocrystal
formulation prepared above was pipetted into a 2 ml
serum vial. After sealing with rubber septum and
20 aluminum cap, the samples were subjected to autoclave
at 121°C for 20 min. On cooling to room temperature,
aliquots of samples were retrieved from the vial and
diluted 100 fold with deionized water for particle size
measurement by Photon Correlation Spectroscopy
25 (Microtract).

Example	Core	Surfactant	Mean Particle Size (nm)	
			Before Auto	After Auto
3	Compound A	SA90HEA	55	125
4	Compound A	SA90HEG	87	194
A	Compound A	F108	130	>500
B	Compound A	T908	241	>500
5	Compound B	SA90HEA	77	
6	Compound B	SA90HEG	71	


WO 96/24335

PCT/US96/01439

-17-



Compound A = WIN 8883



Compound B = WIN 70146

5 Comparing to the commercially available
copolymeric surfactants under identical milling and
autoclave conditions, this data demonstrates that the
sugar surfactants, SA90HEA and SA90HEG, resulted in
unexpectedly reduced mean particle size and limited the
10 particle size growth during terminal sterilization of
the nanocrystal formulations.

In addition, tail vein injection of a 4% solution
of SA90HEA and SA90HEG at 30 ml/Kg was well tolerated
by mice. SA90HEA and SA90HEG were tested in a smudge
15 cell evaluation. Both SA90HEG and SA90HEA were devoid
of smudge cell effect.

SA90HEA and SA90HEG also significantly inhibited
the uptake of polystyrene particle by macrophages.

The invention has been described in detail with
20 particular reference to preferred embodiments thereof,
but it will be understood that variations and
modifications can be effected within the spirit and
scope of the invention.


WO 96/24335

PCT/US96/01439

-18-

What is claimed is:

1. Particles consisting essentially of a crystalline drug substance having a surface modifier
- 5 having the structure:



- 10 wherein R is $\text{Ph}(\text{CH}_2)_{10}\text{CO}$ or $\text{C}_{12}\text{H}_{25}\text{NHCO}$ adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm.

2. The particles of claim 1 having an effective average particle size of less than 250 nm.

- 15 3. The particles of claim 1 having an effective average particle size of less than 100 nm.

4. The particles of claim 1 wherein said drug substance is selected from analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives, astringents, beta-adrenoceptor blocking agents, contrast media, corticosteroids, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immuriological agents, lipid regulating
- 20
- 25

WO 96/24335


PCT/US96/01439

-19-


agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin, prostaglandins, radio-pharmaceuticals, sex hormones, anti-allergic agents, stimulants, sympathomimetics, thyroid agents, vasodilators and xanthines.

5 The particles of claim 1 wherein the drug substance is a diagnostic agent.


6 The particles of claim 5 wherein the drug substance is



7 The particles of claim 5 wherein the drug substance is



8 The particles of claim 1 wherein the surface modifier is




9 The particles of claim 1 wherein the surface modifier is

WO 96/24335

PCT/US96/01439

-20-



10. Particles consisting essentially of a discrete phase of 5,17,-1'-(methylsulfonyl)-1'H-pregn-20-yno-[3,2-c]-pyrazol-17-ol having an ethylene oxide propylene-oxide block copolymer adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm.

11. A stable dispersion consisting essentially of a liquid dispersion medium and the particles of claim 1.

12. The dispersion of claim 10 wherein said dispersion medium is water.

13. The dispersion of claim 10 wherein said dispersion medium is selected from the group consisting of safflower oil, ethanol, t-butanol, hexane and glycol.

14. A pharmaceutical composition comprising the particles of claim 1 and a pharmaceutically acceptable carrier therefor.

15. A method of treating a mammal comprising the step of administering to the mammal an effective amount of the pharmaceutical composition of claim 13.

INTERNATIONAL SEARCH REPORT

 Int'l Application No
 PCT/US 96/01439

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K9/14 A61K9/51

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	EP,A,0 688 781 (EASTMAN KODAK COMPANY) 27 December 1995 see the whole document ---	1-9, 11-15
Y	EP,A,0 603 944 (KODAK LIMITED) 29 June 1994 see claims 1-12 ---	1-9, 11-15
Y	EP,A,0 498 482 (STERLING WINTHROP INC.) 12 August 1992 see page 3, line 13 - line 24 see page 5, line 1 - page 8, line 38 -----	1-9, 11-15

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

8 May 1996

Date of mailing of the international search report

17.07.96

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Tzschoppe, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/01439

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0688781	27-12-95	JP-A- 8041094 US-A- 5529897	13-02-96 25-06-96
EP-A-0603944	29-06-94	JP-A- 6228069 US-A- 5457023	16-08-94 10-10-95
EP-A-0498482	12-08-92	US-A- 5145684 AU-B- 642066 AU-B- 1014592 AU-B- 654836 AU-B- 1014792 EP-A- 0499299 IL-A- 100755 JP-A- 4317053 JP-A- 4295420 US-A- 5451393 US-A- 5494683 US-A- 5399363 US-A- 5318767	08-09-92 07-10-93 30-07-92 24-11-94 30-07-92 19-08-92 08-12-95 09-11-92 20-10-92 19-09-95 27-02-96 21-03-95 07-06-94

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/01439

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. claims 1-9, 11-15

2. claim 10

For further information, please see form PCT/ISA/206 dated 30.05.96.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-9, 11-15

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.